166 related articles for article (PubMed ID: 21538124)
21. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results.
Daneshmand S; Quek ML; Stein JP; Lieskovsky G; Cai J; Pinski J; Skinner EC; Skinner DG
J Urol; 2004 Dec; 172(6 Pt 1):2252-5. PubMed ID: 15538242
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
23. Differential expression of CD10 in prostate cancer and its clinical implication.
Dall'Era MA; True LD; Siegel AF; Porter MP; Sherertz TM; Liu AY
BMC Urol; 2007 Mar; 7():3. PubMed ID: 17335564
[TBL] [Abstract][Full Text] [Related]
24. The incidence of lymph node metastases in prostate carcinoma depends not only on tumor characteristics but also on surgical performance and extent of pelvic lymphadenectomy.
Klevecka V; Musch M; Roggenbuck U; Stoerkel S; Kroepfl D
Medicina (Kaunas); 2008; 44(8):601-8. PubMed ID: 18791337
[TBL] [Abstract][Full Text] [Related]
25. [Extended sentinel lymph node dissection in radical prostatectomy for prostate cancer: a study in the Kiel risk population].
Hautmann S; Beitz S; Naumann M; Lützen U; Seif C; Stübinger SH; van der Horst C; Braun PM; Leuschner I; Henze E; Jünemann KP
Urologe A; 2008 Mar; 47(3):299-303. PubMed ID: 18273596
[TBL] [Abstract][Full Text] [Related]
26. Contemporary Patterns of Care and Outcomes of Men Found to Have Lymph Node Metastases at the Time of Radical Prostatectomy.
Zareba P; Eastham J; Scardino PT; Touijer K
J Urol; 2017 Nov; 198(5):1077-1084. PubMed ID: 28625507
[TBL] [Abstract][Full Text] [Related]
27. [Outcome after radical prostatectomy with extended pelvic lymphadenectomy for untreated high-risk clinically localized prostate cancer].
Tsurusaki T; Yamasaki Y; Maruta S
Nihon Hinyokika Gakkai Zasshi; 2013 May; 104(3):496-504. PubMed ID: 23819361
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy.
Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA
Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390
[TBL] [Abstract][Full Text] [Related]
29. [Lymph node positive prostate carcinoma. A case for radical prostatectomy].
Wirth M; Manseck A
Urologe A; 1999 Jul; 38(4):344-8. PubMed ID: 10444792
[TBL] [Abstract][Full Text] [Related]
30. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
Heidenreich A; Varga Z; Von Knobloch R
J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
[TBL] [Abstract][Full Text] [Related]
31. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.
Fleischmann A; Schlomm T; Huland H; Köllermann J; Simon P; Mirlacher M; Salomon G; Chun FH; Steuber T; Simon R; Sauter G; Graefen M; Erbersdobler A
Clin Cancer Res; 2008 Dec; 14(23):7838-42. PubMed ID: 19047112
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer cell phenotypes based on AGR2 and CD10 expression.
Ho ME; Quek SI; True LD; Morrissey C; Corey E; Vessella RL; Dumpit R; Nelson PS; Maresh EL; Mah V; Alavi M; Kim SR; Bagryanova L; Horvath S; Chia D; Goodglick L; Liu AY
Mod Pathol; 2013 Jun; 26(6):849-59. PubMed ID: 23348903
[TBL] [Abstract][Full Text] [Related]
33. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.
von Bodman C; Godoy G; Chade DC; Cronin A; Tafe LJ; Fine SW; Laudone V; Scardino PT; Eastham JA
J Urol; 2010 Jul; 184(1):143-8. PubMed ID: 20478587
[TBL] [Abstract][Full Text] [Related]
34. Pelvic lymph node dissection in prostate cancer.
Briganti A; Blute ML; Eastham JH; Graefen M; Heidenreich A; Karnes JR; Montorsi F; Studer UE
Eur Urol; 2009 Jun; 55(6):1251-65. PubMed ID: 19297079
[TBL] [Abstract][Full Text] [Related]
35. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection.
Burkhard FC; Bader P; Schneider E; Markwalder R; Studer UE
Eur Urol; 2002 Aug; 42(2):84-90; discussion 90-2. PubMed ID: 12160577
[TBL] [Abstract][Full Text] [Related]
36. Topography of lymph node metastases in prostate cancer patients undergoing radical prostatectomy and extended lymphadenectomy: results of a combined molecular and histopathologic mapping study.
Heck MM; Retz M; Bandur M; Souchay M; Vitzthum E; Weirich G; Mollenhauer M; Schuster T; Autenrieth M; Kübler H; Maurer T; Thalgott M; Herkommer K; Gschwend JE; Nawroth R
Eur Urol; 2014 Aug; 66(2):222-9. PubMed ID: 23465520
[TBL] [Abstract][Full Text] [Related]
37. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience.
Pierorazio PM; Gorin MA; Ross AE; Feng Z; Trock BJ; Schaeffer EM; Han M; Epstein JI; Partin AW; Walsh PC; Bivalacqua TJ
Prostate; 2013 Nov; 73(15):1673-80. PubMed ID: 24019101
[TBL] [Abstract][Full Text] [Related]
38. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
Palapattu GS; Allaf ME; Trock BJ; Epstein JI; Walsh PC
J Urol; 2004 Nov; 172(5 Pt 1):1860-4. PubMed ID: 15540739
[TBL] [Abstract][Full Text] [Related]
39. Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy.
Minardi D; Galosi AB; Giannulis I; Montironi R; Polito M; Muzzonigro G
Scand J Urol Nephrol; 2004; 38(1):19-25. PubMed ID: 15204422
[TBL] [Abstract][Full Text] [Related]
40. Extended vs standard lymph node dissection in robot-assisted radical prostatectomy for intermediate- or high-risk prostate cancer: a propensity-score-matching analysis.
Kim KH; Lim SK; Kim HY; Shin TY; Lee JY; Choi YD; Chung BH; Hong SJ; Rha KH
BJU Int; 2013 Jul; 112(2):216-23. PubMed ID: 23356436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
